150 related articles for article (PubMed ID: 21575929)
21. CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia.
Garcia-Manero G; Scott BL; Cogle CR; Boyd TE; Kambhampati S; Hetzer J; Dong Q; Kumar K; Ukrainskyj SM; Beach CL; Skikne BS
Leuk Res; 2018 Sep; 72():79-85. PubMed ID: 30114559
[TBL] [Abstract][Full Text] [Related]
22. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Svensson T; Chowdhury O; Garelius H; Lorenz F; Saft L; Jacobsen SE; Hellström-Lindberg E; Cherif H
Eur J Haematol; 2014 Nov; 93(5):439-45. PubMed ID: 24853277
[TBL] [Abstract][Full Text] [Related]
23. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
[TBL] [Abstract][Full Text] [Related]
24. Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems.
Sperr WR; Wimazal F; Kundi M; Fonatsch C; Thalhammer-Scherrer R; Schernthaner GH; Schwarzinger I; Haas OA; Geissler K; Lechner K; Valent P
Ann Hematol; 2001 May; 80(5):272-7. PubMed ID: 11446729
[TBL] [Abstract][Full Text] [Related]
25. Proteins of the mitotic checkpoint and spindle are related to chromosomal instability and unfavourable prognosis in patients with myelodysplastic syndrome.
Genga KR; Filho FD; Ferreira FV; de Sousa JC; Studart FS; Magalhães SM; Heredia FF; Pinheiro RF
J Clin Pathol; 2015 May; 68(5):381-7. PubMed ID: 25637637
[TBL] [Abstract][Full Text] [Related]
26. Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes.
Itzykson R; Crouch S; Travaglino E; Smith A; Symeonidis A; Hellström-Lindberg E; Sanz G; Čermák J; Stauder R; Elena C; Germing U; Mittelman M; Langemeijer S; Mądry K; Tatic A; Holm MS; Almeida AM; Savic A; Šimec NG; Luño E; Culligan D; Guerci-Bresler A; Malcovati L; van Marrewijk C; Bowen D; de Witte T; Fenaux P;
Blood Adv; 2018 Aug; 2(16):2079-2089. PubMed ID: 30126931
[TBL] [Abstract][Full Text] [Related]
27. Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
Tong WG; Quintás-Cardama A; Kadia T; Borthakur G; Jabbour E; Ravandi F; Faderl S; Wierda W; Pierce S; Shan J; Bueso-Ramos C; Kantarjian H; Garcia-Manero G
Cancer; 2012 Sep; 118(18):4462-70. PubMed ID: 22252728
[TBL] [Abstract][Full Text] [Related]
28. Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome.
Diamantopoulos PT; Charakopoulos E; Symeonidis A; Kotsianidis I; Viniou NA; Pappa V; Pontikoglou C; Tsokanas D; Drakos G; Kourakli A; Solomou E; Hatzimichael E; Pouli A; Kotsopoulou M; Asmanis E; Dimou M; Panayiotidis P; Papageorgiou S; Vassilopoulos G; Anagnostopoulos A; Vassilakopoulos T; Papadaki H; Galanopoulos A
Sci Rep; 2022 Oct; 12(1):17914. PubMed ID: 36289284
[TBL] [Abstract][Full Text] [Related]
29. The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution.
Zhao WL; Xu L; Wu W; Yan H; Tang W; Hu J; Chen Y; Li JM; Zeng XY; Xiong SM; Shen ZX; Chen Z; Wang ZY; Chen SJ
Hematol J; 2002; 3(3):137-44. PubMed ID: 12111649
[TBL] [Abstract][Full Text] [Related]
30. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.
Kantarjian H; Fenaux P; Sekeres MA; Becker PS; Boruchov A; Bowen D; Hellstrom-Lindberg E; Larson RA; Lyons RM; Muus P; Shammo J; Siegel R; Hu K; Franklin J; Berger DP
J Clin Oncol; 2010 Jan; 28(3):437-44. PubMed ID: 20008626
[TBL] [Abstract][Full Text] [Related]
32. Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients.
Yabe M; Medeiros LJ; Tang G; Wang SA; P Patel K; Routbort M; Bhagat G; Bueso-Ramos CE; Jorgensen JL; Luthra R; Chen W; Muzzafar T; Kanagal-Shamanna R; Khoury JD; Daneshbod Y; Davanlou M; Li S; Young KH; Miranda RN
Hum Pathol; 2016 Apr; 50():109-17. PubMed ID: 26997444
[TBL] [Abstract][Full Text] [Related]
33. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases.
Bourgeois E; Caulier MT; Rose C; Dupriez B; Bauters F; Fenaux P
Leukemia; 2001 Jun; 15(6):950-3. PubMed ID: 11417482
[TBL] [Abstract][Full Text] [Related]
34. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
Kantarjian H; O'Brien S; Ravandi F; Cortes J; Shan J; Bennett JM; List A; Fenaux P; Sanz G; Issa JP; Freireich EJ; Garcia-Manero G
Cancer; 2008 Sep; 113(6):1351-61. PubMed ID: 18618511
[TBL] [Abstract][Full Text] [Related]
35. Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes.
Martín M; de Paz R; Jiménez-Yuste V; Fernández Bello I; García Arias Salgado E; Alvarez MT; Butta NV
Thromb Haemost; 2013 May; 109(5):909-19. PubMed ID: 23407717
[TBL] [Abstract][Full Text] [Related]
36. Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients.
Saeed L; Patnaik MM; Begna KH; Al-Kali A; Litzow MR; Hanson CA; Ketterling RP; Porrata LF; Pardanani A; Gangat N; Tefferi A
Blood Cancer J; 2017 Mar; 7(3):e550. PubMed ID: 28362440
[TBL] [Abstract][Full Text] [Related]
37. IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes.
Wang N; Wang F; Shan N; Sui X; Xu H
Acta Haematol; 2017; 138(3):143-151. PubMed ID: 28873367
[TBL] [Abstract][Full Text] [Related]
38. [Analysis of clinical features and prognosis of primary myelodysplastic syndromes with myelofibrosis patients].
Su T; Zhang PH; Xu ZF; Chen HS; Qin TJ; Zhang Y; Zhang HL; Fan LW; Pan LJ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):378-82. PubMed ID: 22781796
[TBL] [Abstract][Full Text] [Related]
39. Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients.
Breccia M; Latagliata R; Cannella L; Carmosino I; Santopietro M; Loglisci G; Federico V; Alimena G
Leuk Lymphoma; 2010 May; 51(5):783-8. PubMed ID: 20302387
[TBL] [Abstract][Full Text] [Related]
40. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
Wang XQ;
Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
